argenx SE (NASDAQ:ARGX) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of argenx SE (NASDAQ:ARGXGet Free Report) have been assigned a consensus rating of “Moderate Buy” from the twenty-one ratings firms that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation, fourteen have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $520.68.

A number of research analysts have weighed in on the company. Wolfe Research assumed coverage on argenx in a research note on Thursday, February 15th. They set a “peer perform” rating on the stock. JPMorgan Chase & Co. dropped their price objective on argenx from $560.00 to $500.00 and set an “overweight” rating for the company in a report on Monday, May 13th. HC Wainwright dropped their price objective on argenx from $451.00 to $448.00 and set a “buy” rating for the company in a report on Friday, May 10th. Robert W. Baird dropped their price objective on argenx from $505.00 to $490.00 and set an “outperform” rating for the company in a report on Friday, March 1st. Finally, Truist Financial upped their price objective on argenx from $370.00 to $440.00 and gave the stock a “buy” rating in a report on Tuesday, March 5th.

Check Out Our Latest Report on argenx

Hedge Funds Weigh In On argenx

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Parkside Financial Bank & Trust bought a new position in shares of argenx during the third quarter worth about $28,000. GAMMA Investing LLC lifted its position in shares of argenx by 420.0% during the first quarter. GAMMA Investing LLC now owns 78 shares of the company’s stock worth $31,000 after purchasing an additional 63 shares during the last quarter. FNY Investment Advisers LLC bought a new position in shares of argenx during the fourth quarter worth about $38,000. Mather Group LLC. bought a new position in shares of argenx during the first quarter worth about $38,000. Finally, Benjamin F. Edwards & Company Inc. bought a new position in shares of argenx during the fourth quarter worth about $60,000. 60.32% of the stock is owned by hedge funds and other institutional investors.

argenx Stock Up 1.7 %

Shares of argenx stock opened at $385.00 on Thursday. argenx has a fifty-two week low of $327.73 and a fifty-two week high of $550.76. The firm has a market cap of $22.88 billion, a PE ratio of -68.02 and a beta of 0.65. The business’s fifty day moving average is $377.07 and its two-hundred day moving average is $394.56.

argenx (NASDAQ:ARGXGet Free Report) last issued its quarterly earnings results on Monday, May 13th. The company reported ($1.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.33). argenx had a negative return on equity of 14.14% and a negative net margin of 22.58%. The business had revenue of $412.51 million for the quarter, compared to analysts’ expectations of $404.03 million. During the same period in the prior year, the company earned ($0.52) EPS. Equities research analysts anticipate that argenx will post -2.69 EPS for the current year.

argenx Company Profile

(Get Free Report

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.

Featured Articles

Analyst Recommendations for argenx (NASDAQ:ARGX)

Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.